Home
Events
Targeting the Trio: Semaglutide for Managing Cardiovascular, Kidney, and Metabolic Risks

Targeting the Trio: Semaglutide for Managing Cardiovascular, Kidney, and Metabolic Risks

Friday, 6 November 2026 at 9:30 pm GMT+5:30 · Tech team

Dr. Sanjay Kalra, a leading endocrinologist with over two decades of experience talks on the use of semaglutide for managing cardiovascular, kidney, and metabolic risks in patients. Dr. Kalra currently serves as the Treasurer of the International Society of Endocrinology (ISE) and Vice-President of…

We use cookies to ensure the proper functioning of the platform and to improve your experience. This includes strictly necessary cookies and optional analytics cookies. If you reject optional cookies, only cookies necessary to provide you the services will be used. You may change your preferences at any time by clicking ‘’.

·